All In Biotech

Drug Trial Radar · NCT01740063

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

Randomized, Double-blind, Placebo-controlled Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza.

Last checked: Nov 19, 2026Latest source record: Jul 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 423 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

423

Actual

Start

Nov 2012

Primary completion

Jan 2014

Study completion Jan 2014

Sponsor

Lead sponsor
Ansun Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Dec 4, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This protocol will seek to enroll 372 adult otherwise healthy subjects presenting with influenza-like illness (ILI). Subjects will enter the study based on listed inclusion/exclusion criteria, including a positive Rapid Antigen Test (RAT) for influenza virus (IFV). Subjects will be randomized into one of three treatment groups: a DAS181 30 mg total dose group (DAS181-F02 formulation), a DAS181 60 mg total dose group (DAS181-F04 formulation) or a placebo group. The modified intent to treat (mITT) analysis set will include subjects with confirmed influenza as documented by qPCR or TCID50. The full analysis set will be used for activity analysis and will include all randomized subjects with baseline and treatment data. Per protocol, the safety analysis sets are described below in statistical methods. A subpopulation of 60 participants will also have additional PK and Immunogenicity blood samples collected. For this subgroup, PK and Immunogenicity samples will be collected at all study visits.

Conditions

  • Influenza

Interventions

  • DAS181-F02 formulationDrug

  • DAS181-F04 formulationDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Unacceptable Serious Adverse Events due to safety and toxicity Safety and toxicity profile: Unacceptable Serious Adverse Events Safety and toxicity profile: Unacceptable Serious Adverse EventsTime frame: Participants will be followed (up to one year) for the duration of the study and outcome measure will be reviewed at the end of study. The expected end of study is Sept. 2013.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nexbio

    San Diego, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.